Prostate Cancer Surgical Practice Guidelines

ONCOLOGY

Volumn 11, Issue 6, 1997, Pages 907-912

  Richie, Jerome P ^a   Murphy, Gerald P ^b   Walther, Philip ^c  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c DUKE CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER STAGING; HUMAN; MALE; MASS SCREENING; METHODOLOGY; MORTALITY; ONCOLOGY; PHYSICIAN ATTITUDE; PRACTICE GUIDELINE; PROSTATE TUMOR; SURVIVAL RATE;

HUMANS; MALE; MASS SCREENING; MEDICAL ONCOLOGY; NEOPLASM STAGING; PHYSICIAN'S ROLE; PROSTATIC NEOPLASMS; SURVIVAL RATE;

EID: 0031159033     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Cancer Facts & Figures - 1996. Atlanta. American Cancer Society, 1996.
2. Mettlin C, Jones G, Averette H, et al: Defining and updating the American Cancer Society guidelines for the cancer-related check-up: Prostate and endometrial cancer. CA Cancer J Clin 43(1):42-46, 1993.
3. Murphy GP: Prostate cancer: Here and now. CA Cancer J Clin 45(3):133, 1995.
4. Slawin KM, Ohori M, Dillioglugil O, et al: Screening for prostate cancer: An analysis of the early experience. CA Cancer J Clin 45(3):134-147, 1995.
5. Brawer MK: How to use prostate-specific antigen in the early detection or screening for prostatic carcinoma CA Cancer J Clin 45(3):148-164, 1995.
6. Denis LJ, Murphy GP, Schröder FH: Report of the Consensus Workshop on Screening and Global Strategy for Prostate Cancer. Cancer 75(5):1187-1207, 1995.
7. Partin AW, Yoo J, Carter HB, et al: The use of prostate specific antigen, clinical stage, and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol 150:110-4, 1993
8. Labrie F, Dupont A, Cusan L: Downstaging of localized prostate cancer by neoadjuvant therapy with flutamide and Lupron: The first controlled and randomized trial. Clin Invest Med 16:499-509, 1993.
9. Wolf LS Jr, Shinohara K, Carroll PR, et al: Combined role of transrectal ultrasonography, Gleason score, and prostate-specific antigen in predicting organ-confined prostate cancer. Urology 41:207-216, 1993.
10. Mettlin C, Murphy GP, Menck H: Trends in treatment of localized prostate cancer by radical prostatectomy: Observations from the Commission on Cancer National Cancer Database, 1985-1990. Urology 43(4):488-492, 1993.
11. Murphy GP, Mettlin C, Menck H, et al: National patterns of prostate cancer treatment by radical prostatectomy: Results of a survey by the American College of Surgeons Commission on Cancer. J Urol 152(suppl):1817-1819, 1994.
12. Hanks GE, Krall JM, Hanlon AL, et al: Patterns of care and RTOG studies in prostate cancer: Long-term survival, hazard rate observations, and possibilities of cure. Int J Radiat Oncol Biol Phys 28:39-45, 1994.
13. Bagshaw MA, Kaplan ID, Cox R: Radiation therapy for localized disease. Cancer 71:939-52, 1993.
14. Porter AT, Blasko JC, Grimm PD, et al: Brachytherapy for prostate cancer. CA Cancer J Clin 45(3):165-178, 1995.
15. Johansson J, Adami A, Andersson S, et al: High 10 year survival rate in patients with early, untreated prostate cancer. JAMA 267:2191-6, 1992.
16. Whitmore WF, Warner JA, Thompson IM: expectant management of localized prostatic cancer. Cancer 67:1091-1096, 1991.
17. 111In-labeled monoclonal antibody 7E11.C5.3 (CYT-356). Prostate 18(3):229-241, 1991.
18. Murphy GP: Radioscintiscanning of prostate cancer. Cancer 75(7; suppl):1819-1822, 1995.
19. Murphy GP: Follow-up evaluation of National Prostatic Cancer Project protocols and other studies. Urology 44(6A):61-66, 1994.
20. Murphy GP, Holmes EH, Boynton AL, et al: Comparison of prostate specific antigen, prostate specific membrane antigen, and LNCaP-based enzyme-linked immunosorbent assays in prostatic cancer patients and patients with benign prostatic enlargement. Prostate 26(3):164-168, 1995.